Table 1.

Summary of inhibitors for spike protein.

Type of inhibitor	Target of inhibitor	Inhibitor	IC50 (Pseudovirus)	IC50 (Authentic virus)	Kd	EC50	ND50	Reference
Chemical compounds	HR1 and HR2	EK1C4	15.8 nM	36.5 nM	-	-	-	(Xia et al., 2020)
	HR2	IPB02	80 nM	-	-	-	-	(Zhu et al., 2020)
	COVID-19	Glycyrrhizic acid	-	Reduces IC50 by about 10-fold	-	-	-	(Bailly and Vergoten, 2020)
	ACE2	Captopril	-	-	-	-	-	(Biyani et al., 2020)
		Enalapril	-	-	-	-	-	(Sharif-Askari et al., 2020)
		ARB	-	-	-	-	-	(Chung et al., 2020)
		Lisinopril	-	-	-	-	-	(Khelfaoui et al., 2020)
Neutralizing antibodies	Spike	BD-217	0.031 μg/ml	0.84 μg/ml	0.29 nM	-	-	(Cao Y. et al., 2020)
		BD-218	0.011 μg/ml	0.29 μg/ml	0.039 nM	-	-	(Cao Y. et al., 2020)
		BD-236	0.037 μg/ml	0.52 μg/ml	2.8 nM	-	-	(Cao Y. et al., 2020)
		BD-361	0.020 μg/ml	0.780 μg/ml	1.3 nM	-	-	(Cao Y. et al., 2020)
		BD-368	0.035 μg/ml	1.600 μg/ml	1.2 nM	-	-	(Cao Y. et al., 2020)
		BD-368-2	0.001.2 μg/ml	0.015 μg/ml	0.82 nM	-	-	(Cao Y. et al., 2020)
		BD-395	0.020 μg/ml	0.270 μg/ml	0.36 nM	-	-	(Cao Y. et al., 2020)
		2B04	1.46 ng/ml	-	-	-	-	(Alsoussi et al., 2020)
		CA1	-	-	4.68 ± 1.64 nM	-	0.38 μg/ml	(Shi et al., 2020)
		CB6	-	-	2.49 ± 1.65 nM	-	0.036 ± 0.007 μg/ml	(Shi et al., 2020)
		P2C-1F11	0.03 μg/ml	0.03 μg/ml	2.12 nM	-	-	(Ju et al., 2020)
		P2B-2F6	0.05 μg/ml	0.41 μg/ml	5.14 nM	-	-	(Ju et al., 2020)
		P2C-1A3	0.62 μg/ml	0.28 μg/ml	2.47 nM	-	-	(Ju et al., 2020)
		S309 Fab	-	79 ng/ml	0.81 nM	-	-	(Pinto et al., 2020)
		H11-H4-Fc	61 nM	-	5.5 nM	-	6 nM	(Huo et al., 2020)
		H11-D4-Fc	161 nM	-	10 nM	-	18 nM	(Huo et al., 2020)
		VHH72-Fc	262 nM	-	40nM	-	0.2 μg/ ml	(Huo et al., 2020)
		CR3022 Fab	347 nM	-	115 nM	-	-	(Yuan et al., 2020a)
		CR3022 IgG	-	-	1 nM	-	-	(Yuan et al., 2020a)
		H014 Fab	3 nM	38 nM	0.096 nM	0.7 nM	-	(Lv et al., 2020)
		REGN10933	42.8 pM	37.4 pM	3.37 nM	5.79 pM	-	(Baum et al., 2020)
		REGN10987	40.6 pM	42.1 pM	45.2 nM	6.33 pM	-	(Baum et al., 2020)
		REGN10989	7.23 pM	7.38 pM	3.65 nM	4.86 pM	-	(Baum et al., 2020)
		REGN10934	54.4 pM	28.3 pM	4.86 nM	2.72 pM	-	(Baum et al., 2020)
		C105 Fab	26.1 ng/mL	-	-	-	-	(Barnes et al., 2020)
		CV30	0.03 μg/mL	-	3.6 nM	-	-	(Hurlburt et al., 2020)
		EY6A	54 nM	-	2 nM	-	0.5 nM	(Zhou et al., 2020)
		CC12.1Fab	20 ng/ml	20 ng/ml	17 nM	-	-	(Yuan et al., 2020a)
		CC12.3 Fab	20 ng/ml	20 ng/ml	14 nM	-	-	(Yuan et al., 2020a)
		COVA2-39	0.036 µg/ml	0.054 µg/ml	21 nM	-	-	(Wu N. C. et al., 2020)
		COVA2-04	0.22 µg/ml	2.5 µg/ml	40 nM	-	-	(Wu N. C. et al., 2020)
		4A8	-	0.39 μg/ml	92.7 nM	0.61μg/ml	-	(Chi et al., 2020)
Nanobody		Ty1	54 nM	-	5–10 nM	-	-	(Hanke et al., 2020)

IC₅₀, half maximal inhibitory concentration; Kd, dissociation constant; EC₅₀, concentration for half of maximal effect; ND₅₀, half neutralizing dose.